Zydus, Apollo Hospitals Rally on Cancer Test Partnership


    By Dalal Street Investment Journal (DSIJ)

    Summary :

     

    Zydus Lifesciences and Apollo Hospitals shares rose after the companies partnered to introduce the Shield Multi-Cancer Detection blood test in India. While Apollo Hospitals touched a new all-time high, Zydus Lifesciences climbed to a fresh 52-week high as investors cheered the development.

    Zydus Lifesciences and Apollo Hospitals remained in focus during the afternoon session on Friday, July 3. Buying interest picked up after the companies announced a partnership that could strengthen cancer screening in India.

    Zydus Lifesciences share price gained over 3% and climbed to its 52-week high. Apollo Hospitals share price also advanced more than 2% and touched a fresh all-time high of ₹8,918 during the session.

    What Triggered the Rally?

    Zydus Lifesciences announced that it has entered into an exclusive agreement with Guardant Health Inc. to make the Shield Multi-Cancer Detection (MCD) test available in India. As part of this arrangement, Zydus signed a Memorandum of Understanding with Apollo Hospitals to offer the test across the country.

    The Shield MCD test is a methylation-based blood test designed to detect multiple cancers through a single blood sample. It screens for 10 common cancers, including breast, lung, colorectal, prostate, liver, pancreatic, ovarian, bladder, gastric and oesophageal cancers. The test is meant for individuals aged 45 years or above who are considered to be at average risk of developing cancer.

    Zydus Lifesciences Ltd

    Trade

    1140.640.79 (3.70 %)

    Updated - 03 July 2026
    1142.90day high
    DAY HIGH
    1104.10day low
    DAY LOW
    1860457
    VOLUME (BSE)

    Why This Partnership Matters

    The announcement goes beyond a routine business agreement. It addresses a major healthcare challenge in India. Cancer is one of the leading causes of death in the country. More than 1.41 million people were diagnosed with cancer in 2022, while over 900,000 people lost their lives. Additionally, cancer screening rates remain low in the country.

    About Apollo Hospitals Enterprise Ltd

    Apollo Hospitals Enterprise Ltd was founded in 1979 by Dr. Prathap C. Reddy. It has grown into India's largest integrated hospital chain with 78 hospitals and a capacity of 10,970 census beds.

    As of 3:02 pm on July 3, Apollo Hospitals share price was trading at ₹8,890.50, up 2.24% for the day. During the session, the stock touched a fresh all-time high of ₹8,920. It has gained over 25% so far in 2026.

    About Zydus Lifesciences Ltd

    Zydus Lifesciences Ltd was established in 1952 as Cadila Laboratories by Raman Patel and Indravadan Modi. The company adopted its current name in February 2022. Today, the company is recognised as one of the leading pharmaceutical companies in India. Its businesses span branded formulations, generics, consumer wellness, animal healthcare and active pharmaceutical ingredients. It also has a strong presence in the US, where it ranks among the top five generic drug companies by prescriptions.

    As of 3:04 pm on July 3, Zydus Lifesciences share price was trading at ₹1,141.40, up 3.78% for the day. The stock also climbed to a fresh 52-week high during the session. It has delivered a gain of nearly 25% so far in 2026.

    Source: Dalal Street Investment Journal (DSIJ), NSE

    About the Author

    SEBI Registered Research Analyst (INH000006396).


    Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise. 

    Published Date : 03 Jul 2026

    Disclaimer :

    Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text